Keith Gottesdiener, Prime Medicine CEO
Updated: Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers
Prime Medicine is cutting its pipeline, but gaining a partner.
The gene editing company, which once boasted a pipeline of 18 programs, is now focusing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
